MX2010009488A - Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor. - Google Patents

Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor.

Info

Publication number
MX2010009488A
MX2010009488A MX2010009488A MX2010009488A MX2010009488A MX 2010009488 A MX2010009488 A MX 2010009488A MX 2010009488 A MX2010009488 A MX 2010009488A MX 2010009488 A MX2010009488 A MX 2010009488A MX 2010009488 A MX2010009488 A MX 2010009488A
Authority
MX
Mexico
Prior art keywords
receptor
modulating
activity
treatment
methods
Prior art date
Application number
MX2010009488A
Other languages
English (en)
Inventor
Arnold Thomas Blaskovich Mark
Joseph Cassidy Peter
Original Assignee
Mimetica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/391,748 external-priority patent/US8377925B2/en
Application filed by Mimetica Pty Ltd filed Critical Mimetica Pty Ltd
Publication of MX2010009488A publication Critical patent/MX2010009488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) que son útiles para modular la actividad biológica del receptor de melanocortina 5 (MC5R). Los compuestos de esta invención se pueden emplear para tratar enfermedades y/o afecciones en las que la reducción de MC5R es beneficiosa. Estas enfermedades y/o afecciones incluyen, pero no se limitan a, acné, seborrea, dermatitis seborreica, cáncer y enfermedades inflamatorias.
MX2010009488A 2008-02-29 2009-02-27 Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor. MX2010009488A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3291208P 2008-02-29 2008-02-29
US12/391,748 US8377925B2 (en) 2008-02-29 2009-02-24 Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
PCT/AU2009/000231 WO2009105824A1 (en) 2008-02-29 2009-02-27 Methods of modulating the activity of the mc5 receptor and treatment of conditions related to this receptor

Publications (1)

Publication Number Publication Date
MX2010009488A true MX2010009488A (es) 2011-03-02

Family

ID=41015441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009488A MX2010009488A (es) 2008-02-29 2009-02-27 Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor.

Country Status (12)

Country Link
EP (1) EP2257297B1 (es)
JP (1) JP5503558B2 (es)
KR (1) KR101620115B1 (es)
CN (1) CN102006873B (es)
AU (1) AU2009219107B2 (es)
BR (1) BRPI0907906A2 (es)
CA (1) CA2716316C (es)
IL (1) IL207833B (es)
MX (1) MX2010009488A (es)
NZ (1) NZ587361A (es)
RU (1) RU2555343C9 (es)
WO (1) WO2009105824A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
MX2010009486A (es) * 2008-02-29 2011-02-22 Mimetica Pty Ltd Antagonistas de tipo 1,4-diazepan 2 ona 3-sustituida del receptor de melanocortina-5.
WO2016174011A1 (en) * 2015-04-28 2016-11-03 Cutech Srl Compositions comprising valerian extracts
GB201808149D0 (en) 2018-05-18 2018-07-11 Univ Court Univ Of Glasgow Protected amino acids
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法
CN115232015B (zh) * 2022-07-06 2024-01-02 暨明医药科技（苏州）有限公司 一种氯喹手性侧链的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas blanghard
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
CN1816337A (zh) * 2003-05-01 2006-08-09 帕拉坦技术公司 黑素皮质素受体特异性化合物
WO2008017852A1 (en) * 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
MX2010009486A (es) * 2008-02-29 2011-02-22 Mimetica Pty Ltd Antagonistas de tipo 1,4-diazepan 2 ona 3-sustituida del receptor de melanocortina-5.

Also Published As

Publication number Publication date
BRPI0907906A2 (pt) 2020-08-18
CN102006873A (zh) 2011-04-06
IL207833B (en) 2018-02-28
NZ587361A (en) 2012-07-27
AU2009219107B2 (en) 2013-11-21
RU2555343C2 (ru) 2015-07-10
CN102006873B (zh) 2013-09-18
CA2716316C (en) 2017-05-30
RU2010137030A (ru) 2012-04-10
KR101620115B1 (ko) 2016-05-12
RU2555343C9 (ru) 2015-11-27
EP2257297B1 (en) 2017-10-18
JP5503558B2 (ja) 2014-05-28
IL207833A0 (en) 2010-12-30
EP2257297A4 (en) 2012-02-22
WO2009105824A1 (en) 2009-09-03
KR20100134614A (ko) 2010-12-23
CA2716316A1 (en) 2009-09-03
AU2009219107A1 (en) 2009-09-03
JP2011513245A (ja) 2011-04-28
EP2257297A1 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
MX2010009488A (es) Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor.
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
UA99839C2 (ru) Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
NZ700928A (en) Dna-pk inhibitors
PH12013502369A1 (en) Diazacarbazoles and methods of use
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
JO3131B1 (ar) مركبات كيميائية
TN2012000555A1 (en) Antibodies to human gdf8
MX2010004074A (es) Combinacion 059.
MX2011013816A (es) Pirimidinonas como inhibidores de pi3k.
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
TN2011000627A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2011011735A (es) Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
MY161656A (en) Therapeutic use of diaminophenothiazines
EA019744B9 (ru) Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами
NZ597075A (en) 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MY186456A (en) Quinazoline carboxamide azetidines
EA201100874A1 (ru) Соединения для лечения рака
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.
MX348024B (es) Compuestos de adamantilo.

Legal Events

Date Code Title Description
FG Grant or registration